Managed Healthcare Executive October 9, 2025
Panelists discuss how bimekizumab represents a valuable addition to the psoriatic arthritis treatment armamentarium, given its novel dual mechanism, ability to address multiple disease domains and potential to benefit patients who have lost response to other biologics, reducing healthcare burden and improving societal economic outcomes.
Despite significant therapeutic advances in psoriatic arthritis treatment, substantial unmet medical needs persist, with many patients failing to achieve treatment goals even with current options. Bimekizumab addresses this gap by providing a new medication and a novel mechanism of action through comprehensive IL-17A and IL-17F inhibition, distinguishing it from existing IL-17A-only inhibitors. The phenomenon of gradual or sudden efficacy loss affects virtually all psoriatic arthritis medications over time, necessitating additional therapeutic options with distinct mechanisms...
Today's Sponsors
Today's Sponsor